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Abstract
Background: Steroid-responsive meningitis-arteritis (SRMA) is a systemic inflammatory disease affecting young
adult dogs and a potential large animal model for neutrophilic meningitis. Similarities between SRMA and
infectious central nervous system (CNS) diseases in lymphocyte subsets suggest an infectious origin.
Toll-like receptors (TLRs) are pattern recognition receptors playing an important role in innate immunity. Due to
their ability to recognize both self and non-self antigens, we hypothesize that TLRs are among the key factors for
the induction of the inflammatory process in SRMA and provide an indirect hint on the etiology of the disease.
Methods: The expression profile of cell surface TLRs (TLR2, TLR4 and TLR5) and intracellular TLRs (TLR3 and TLR9) of
canine leukocytes was analyzed by immunophenotyping and subsequent flow cytometric measurements.
Experiments were performed on cerebrospinal fluid (CSF) and peripheral blood (PB) samples of dogs affected with
SRMA during the acute phase (n = 14) as well as during treatment (n = 23) and compared with those of dogs with
bacterial meningitis (n = 3), meningoencephalitis of unknown etiology (n = 6), neoplasia of the central nervous
system (n = 6) and a group of dogs with miscellaneous neurological diseases (n = 9). Two additional control groups
consisted of dogs with pyogenic infections (n = 13) and of healthy dogs (n = 6).
Results: All examined groups showed a high percentage of TLR2, TLR4 and TLR5 positive PB polymorphonuclear
cells (PMNs) in comparison to healthy dogs. Very high values of TLR9 positive PB PMNs were detected in acute
SRMA. Only a few similarities were found between SRMA patients and dogs with pyogenic infections, both groups
were characterized by high expression of TLR4 positive PB monocytes. Glucocorticosteroid therapy reduced TLR2,
TLR4 and TLR9 expression in PB monocytes.
Conclusions: A relatively high expression of TLR4 and TLR9 in acute SRMA suggests that these two receptors might
be involved in the inflammatory process in SRMA, enhancing the autoimmune reaction. Systematic CSF cell analysis
for TLRs can be performed in future treatment studies in larger animals, such as dogs.
Background
Steroid-responsive meningitis-arteritis (SRMA) is a sys-
temic inflammatory disease affecting young adult dogs. It
is the most common cause of meningitis [1] and the most
common cause of fever of unknown origin in dogs [2].
In recent years SRMA has become well-recognized in
veterinary practice, although a deep understanding of the
disease is still lacking. Similarities between SRMA and
infectious central nervous system (CNS) diseases in
lymphocyte subsets suggest that the immune response in
SRMA might be triggered by an antigen [3]. However,
such infectious agents were not directly detected [4].
SRMA has been proposed to be a potential large animal
model for Kawasaki disease [5], especially since system-
atic flow cytometric (FACS) analysis of CSF is feasible in
larger animals, such as dogs [6].
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Toll-like receptors (TLRs) are pattern recognition recep-
tors which recognize both invading pathogens (through
pathogen-associated molecular patterns, PAMPs) and
endogenous molecules produced by injured tissue (through
damage-associated molecular patterns, DAMPs) [7].
This recognition process plays a role in innate immun-
ity and in the development of the adaptive immune
response [8,9]. Additionally, TLRs may be involved in the
induction of chronic inflammation and autoimmune
reactions [9-12]. There are many examples of systemic
human diseases in which an association with TLRs has
been found [13], including systemic lupus erythematosus
[14], giant cell arteritis [15,16], Sjögren’s syndrome [17],
autoimmune arthritis [18] and multiple sclerosis [19]. In
dogs, TLRs have been found up-regulated in inflamma-
tory bowel disease [20]. The TLR expression on CSF leu-
kocytes has not yet been widely studied.
To date, SRMA is believed to be characterized by a
Th2-mediated immune response [21], but it is still
unclear if this reaction is triggered by environmental fac-
tors or self-antigen (hit-and-run principle).
Due to their ability to recognize both self (DAMPs)
and non-self (PAMPS) molecules, TLRs are suspected to
be involved in the inflammatory process in SRMA. To
confirm the hypothesis that SRMA is triggered by an
environmental factor, such as a bacterial infection, which
is specifically changing the TLR pattern, the expression
profile of cell surface TLRs (TLR2, TLR4 and TLR5) and
intracellular TLRs (TLR3 and TLR9) were examined on
canine leukocytes. An indirect hint on the etiology of
SRMA was expected.
Methods
Dog population and samples
The study population consisted of 80 dogs referred to
the Department of Small Animal Medicine and Surgery,
University of Veterinary Medicine, Hannover, Germany
between May 2009 and April 2011. The studies were
conducted according to the ethical guidelines of the
University for Veterinary Medicine Hannover. Depending
on the clinical diagnosis, the dogs were assigned to one of
the following groups (see Table 1).
SRMA Acute (SRMA A): The diagnosis of SRMA was
supported by the detection of typical findings during
physical and neurological examinations, complete blood
and CSF examinations, cervical radiographs, elevated
IgA levels in CSF and serum and the absence of other
conditions causing cervical pain [22]. Dogs with the
acute form of SRMA, but pretreated with glucocorticos-
teroids prior to CSF puncture were excluded from the
study.
SRMA Therapy (SRMA Th): dogs from the former
group under glucocorticosteroid treatment that did not
show clinical signs at the time of sampling. Dogs under
treatment for SRMA received prednisolone, with
dosages ranging from 1 mg/kg/24 h to 0.5 mg/kg/48 h.
The other groups were: bacterial meningitis or menin-
goencephalitis (BM); meningoencephalitis of unknown
etiology (MUE); CNS neoplasia (Neopl) and a group of
dogs with miscellaneous neurological diseases (Mix) (see
Table 1). In dogs with BM, MUE, CNS neoplasia and
dogs with miscellaneous neurological diseases, in addition
to the diagnostic procedures described for SRMA, mag-
netic resonance imaging (MRI), electrophysiological
studies, surgery and histopathology contributed to the
diagnosis.
Since SRMA is considered to be a systemic inflamma-
tory disorder [23], leukocytes from dogs with pyogenic
infections not affecting the nervous system (Pyo) were
evaluated as a further control group. Another control
group (Healthy) consisted of privately owned blood
donors from the hospital and were considered to be
healthy because history, complete physical examination,
blood examination and clinical follow-up examinations
Table 1 Distribution of disease categories
Diseases Findings Number
of dogs
SRMA Acute (SRMA A) Dogs with fever, cervical pain, neutrophilic leukocytosis and pleocytosis, no pre-treatment with
glucocorticosteroid
14
SRMA Therapy (SRMA Th) Dogs from SRMA A group, asymptomatic under long-term glucocorticosteroid treatment 23
Bacterial meningitis (BM) Dogs with meningitis/meningoencephalitis caused by bacterial infections 3
Meningoencephalitis of unknown
etiology (MUE)
Dogs with clinical, CSF, MRI and/or pathological findings consistent with meningoencephalitis, in
which no causative agent has been identified.
6
Neoplasia (Neopl.) Dogs with clinical, CSF, MRI and/or pathological findings consistent with neoplasia of the CNS 6
Miscellaneous (Mix) Dogs with miscellaneous non-inflammatory neurological diseases including intervertebral disc
disease, peripheral nervous system diseases and idiopathic epilepsy
9
Pyogenic infection (Pyo) Dogs suffering from diseases caused by pyogenic infections, such as pyometra, pyothorax and
bacterial peritonitis
13
Healthy Healthy dogs 6
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did not reveal any abnormalities. The owners approved
the blood examinations.
From each dog five mL of blood were collected via
cephalic or saphenous venipuncture into tubes contain-
ing ethylene diamine tetraacetic acid (EDTA) for collec-
tion of peripheral blood (PB) leukocytes.
Cisternal cerebrospinal fluid (CSF) collection under
general anesthesia was part of the work-up in all dogs
for collection of CSF leukocytes with the exception of
healthy animals and patients with pyogenic infections.
Isolation, permeabilization and fixation of peripheral
blood leukocytes
After collection, 1 mL of EDTA PB was used for staining
of cell surface TLRs (TLR2, TLR4 and TLR5) and 0.5 mL
for intracellular staining (TLR3 and TLR9). Leukocytes
were fixed, in order to preserve their marker expression.
For the staining of cell surface TLRs, the cells were
fixed using a previously described method of preparing
blood leukocytes for flow cytometric analysis [24]. The
method has been previously validated from Burgener
and Jungi [25] for detection of TLRs on canine leuko-
cytes. Briefly, the blood was mixed with the same
volume of preheated 0.4% formaldehyde (diluted in phos-
phate buffered saline (PBS; containing 137 mM sodium
chloride, 2.7 mM potassium chloride, 8.1 mM disodium
hydrogen phosphate, 1.5 mM monopotassium phosphate,
pH 7.4)) and incubated for four minutes at 37°C. Succes-
sively, 40 mL of warmed lysing buffer (0.83% ammonium
chloride/0.01 M Tris chloride, pH 7.4) was added and
the mixture was incubated at 37°C until red-cell lysis was
observed (about one to two minutes). After centrifuga-
tion at 160 x g for 10 minutes the supernatant was dis-
carded and the pellet was washed twice with PBS.
For intracellular staining the blood was mixed with BD
FACSTM Lysing Solution, twice its volume, diluted 1:10
(BD Biosciences, Erembodegem, Belgium), and incu-
bated for 10 minutes. After a washing step at 500 x g for
five minutes using PBS containing 1.25% pooled dog
serum, BD FACSTM Permeabilizing Solution 2 was
added for 10 minutes according to the description of the
manufacturer (BD Biosciences). Ultimately, an additional
washing step was performed.
The number of leukocytes was determined in both
procedures using a hemocytometer and the cell suspen-
sion was adjusted to 2.5 105 leukocytes/50 μL using PBS
containing 1.25% pooled dog serum.
Isolation, permeabilization and fixation of cerebrospinal
fluid leukocytes
Immediately after tapping, CSF was aliquoted in two
tubes and centrifuged at 200 x g for 10 minutes, as
described by Schwartz et al. [26].
As described above for blood leukocytes, one CSF
aliquot underwent fixation (cell surface TLRs) and
the other CSF aliquot underwent permeabilization (intra-
cellular TLRs). Both procedures were performed as
described for PB with the exception of the lysing steps.
Monoclonal antibodies (mAbs) and immunostaining
A study from Burgener et al. [25] demonstrated that
commercial antibodies against human TLRs cross-react
with canine TLRs. According to this study, human anti-
bodies were chosen and listed in Table 2. In addition,
antibodies against cell surface antigens were used to
identify leukocyte subclasses, such as lymphocytes (CD3+
or CD21+), polymorphonuclear cells (CD11a+/CD11b+)
and monocytes (CD14+), (see Table 2). The secondary anti-
body was an F(ab’)2-fragment specific RPE-labeled goat-
anti-mouse IgG antibody (Dianova, Hamburg, Germany)
(1:200 dilution).
Negative controls consisted of isotype-matched pri-
mary antibodies (see Table 2) and cell suspensions
stained with the secondary antibody alone.
Incubation was performed for 30 minutes at 4°C under
light protection. The washing steps were performed with
PBS with 1.25% of canine pooled serum in order to pre-
vent unspecific Fc-receptor binding of mAbs.
Flow cytometry
Samples were analyzed using a standard FACSCalibur™
flow cytometer and the BD CellQuest™ Pro Version 5.2.1
software (Becton Dickinson, Heidelberg, Germany).
Leukocyte populations (Figure 1) were gated accord-
ing to light scatter properties and CD expression into
lymphocytes, monocytes and polymorphonuclear cells
(PMNs), as previously described [27].
All events in CSF samples and a minimum of 10,000
events in blood samples were collected.
Statistical analysis
The percentage of positive cells and the mean fluores-
cence intensity (MFI) of each group were used for statis-
tical analysis using a commercial statistical program
(GraphPad Prism 5.0, GraphPad Software, San Diego,
CA, USA). The Wilcoxon rank sum test and the
Kruskal–Wallis one-way analysis of variance were ap-
plied for comparison of the results deriving from the
different groups. Statistical significance was set at the
5% level (P <0.05).
Results
Expression of TLRs on CSF and PB leukocytes
The expression of intracellular and surface TLRs on CSF
and PB leukocytes of untreated dogs affected with
SRMA are summarized in Table 3; results are given as
the percent of positive cells. Statistically relevant results
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among the different leukocyte subsets and disease cat-
egories are shown in Figures 2, 3 and 4.
Expression of TLRs on PMNs
Generally, all groups with diseased dogs displayed a high
percentage of TLR2, TLR4 and TLR5 positive PB PMNs
in comparison to healthy dogs.
In SRMA dogs under treatment a tendency
(P= 0.0669) was noted towards a decreased expression
of TLR2 on PMNs (median 97.5%; range 97.1 to 98.7%)
in comparison to dogs with the acute form of SRMA
(median 98.7%; range 98.1 to 99.3%) (see Figure 2C). In
CSF samples, no significant differences among the
groups were detected. However, the highest values of
TLR2 positive PMNs were seen in dogs in the acute
form of SRMA (SRMA A, median 83.8%; range 79.6 to
90.9%) (see Figure 2D).
SRMA dogs showed higher expression (P= 0.0023) of
TLR4 positive PB PMNs (SRMA A, median 98.6%; range
98.1 to 99.7%) in comparison to healthy controls
(Healthy, median 89.8%; range 82.5 to 93.7%) and to
dogs affected with miscellaneous diseases of the nervous
system (Mix, median 95.6%; range 94 to 97.5%)
(P= 0.0095) (see Figure 2E). In CSF, the highest values of
TLR4 positive PMNs were found in dogs in the acute
stage of SRMA (median 93.1%; range 81.7 to 95.3%) with
significant differences (P <0.05) to cases with encephali-
tides of unknown etiology (MUE, median 67%; range
23.1 to 77.9%) and with CNS neoplasia (Neopl, median
58.1%; range 24 to 70.7%) (see Figure 2F).
All groups of diseased animals had significantly higher
percentages of TLR5 positive PB PMNs (P <0.05) in
comparison to healthy animals (Healthy, median 79.5%;
range 45.7 to 90.6%) (see Figure 2G). In CSF higher per-
centage of TLR5 positive PMNs (P <0.05) was found in
SRMA A (median 91.6%; range 70.9 to 95.3%) in com-
parison with MUE (median 52.1%; range 16.6 to 72.6%)
and Neopl (median 35.8%; range 18.7 to 59.3%) (see
Figure 2H).
Dogs from SRMA A (median 7.5%; range 5.2 to 11%),
SRMA Th (median 6.3%; range 3.9 to 10.4%), Neopl
(median 26.1%; range 8.9 to 35.8%) and Mix (median
7.5%; range 8.9 to 35.8%) groups showed a higher per-
centage of PMNs positive for TLR3 (P <0.05) in com-
parison to dogs with pyogenic infections (Pyo, median
2.4%; range 1.3 to 4.7%). SRMA Th and Pyo dogs had a
significant lower (P <0.05) percentage of TLR3 positive
PMNs in comparison to healthy dogs (see Figure 2A).
No significant differences were found between the
groups examined for expression of TLR3 positive PMNs
Table 2 Monoclonal antibodies
Specificity Name Clone Provider Dilution
CD282/TLR2* mouse anti human CD282 TL2.1 Serotec 1:26
CD283/TLR3* mouse anti human CD283 TLR3.7 Serotec 1:26
CD 284/TLR4* mouse anti human CD284 HTA125 Serotec 1:26
CD289/TLR5* mouse anti human CD289 85B152.5 Acris 1:26
CD289/TLR9* mouse anti human CD289 5 G5 Serotec 1:26
CD3 mouse anti dog CD3 CA17.2A12 Serotec 1:300
CD11a mouse anti dog CD11a CA11.4D3 Serotec 1:300
CD11b mouse anti dog CD11b CA16.3E10 Serotec 1:6
CD14* mouse anti human CD14} TÜK4 Dako 1:15
CD21 mouse anti canine CD21} CA2.1D6 Serotec 1:6
IgG1 mouse IgG1 negative control W3/25 Serotec 1:6
IgG2a mouse IgG2a control} PPV-04 ImmunoTools 1:6
*Reacts with canine species; }RPE-Conjugated.
Figure 1 Population of CSF leukocytes: granulocytes (R1,
green), lymphocytes (R2, pink) and monocytes (R3, red).
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in CSF. However, a lower percentage of TLR3 positive
PMNs was observed in SRMA A (median 2.4%; range
1.5 to 3.7%) in comparison to Neopl (median 10.5 5%;
range 4.3 to 14.8%).
Healthy dogs had the lowest values of TLR9 positive
PB PMNs (Healthy, median 20.82%; range 10.1 to 41.2%)
in comparison to all other groups (P <0.05), with the
exception of MUE and Pyo (see Figure 2B). The highest
values of TLR9 positive PMNs were detected in SRMA A
(median 96.3%; range 60.8 to 97.7%). The groups did not
differ statistically regarding TLR9 positive PMNs in CSF.
In general, the fluorescence expression intensity did
not differ significantly among the groups examined. An
exception was the expression intensity of TLR3 on PB
PMNs, SRMA A had a lower TLR3 MFI in comparison
to Pyo (P= 0.0149) and Healthy (P= 0.0077).
Expression of TLRs on monocytes
Dogs with SRMA, similar to dogs with pyogenic infec-
tions, were characterized by high values of TLR4 positive
PB monocytes. In SRMA dogs, the percentage of TLR2,
TLR4 and TLR 9 positive PB monocytes decreased after
therapy.
The highest percentages of TLR2 positive monocytes
were found in dogs with pyogenic infections (Pyo,
median 96.6%; range 95.4 to 97.9%) and untreated SRMA
dogs (SRMA A, median 96.3%; range 94 to 97.9%), being
significantly higher than in SRMA Th (median 90.7%;
range 88.4 to 95.3%; P<0.01), Neopl (median 90.5%; range
87.7 to 96.4%; P<0.05) and Mix (median 90.3%; range 76.3
Table 3 Expression of TLRs in/on leukocytes in SRMA
(percentage of positive cells, median and 25%
to 75% range)





TLR3 2.4 (1.5 to 3.7) none Neopl"
TLR9 94.1 (53.8 to 99.0) none
TLR2 83.8 (79.6 to 90.9) none
TLR4 93.1 (81.7 to 95.3) MUE#
Neopl#
TLR5 91.6 (70.9 to 95.3) MUE#
Neopl#
CSF monocytes
TLR3 14.4 (3.7 to 30.5) none
TLR9 85.0 (48.0 to 95.0) none MUE#
TLR2 87.0 (78.9 to 94.3) none MUE#
TLR4 82.6 (74.5 to 93.2) none
TLR5 83.3 (62.8 to 94.1) none
CSF lymphocytes
TLR3 2.9 (1.0 to 11.6) none SRMA Th"
TLR9 2.9 (18.8 to 1.5) none mix#
TLR2 13.0 (8.1 to 18.0) BM#
MUE#
TLR4 13.0 (3.0 to 23.9) SRMA Th"
BM#
Mix"
TLR5 11.1 (3.7 to 18.8) none BM#
PB PMNs
TLR3 7.5 (5.3 to 11) Pyo# Neopl"
Healthy"
TLR9 96.3 (60.8 to 97.7) Healthy# Mix#
TLR2 98.7 (98.1 to 99.3) Healthy# SRMA Th#
Mix#
TLR4 98.6 (98.1 to 99.7) Healthy#
Mix#
TLR5 99.0 (97.4 to 99.5) Healthy#
PB monocytes
TLR3 8.6 (4.5. to 15.21) Pyo# Neopl"
Healthy#
TLR9 92.1 (67.2 to 96.9) SRMA Th# Pyo#
Healthy#
TLR2 96.3 (94.0 to 97.9) SRMA Th#
Neopl#
Mix#
TLR4 95.6 (93.3 to 96.9) SRMA Th# Neopl#
Table 3 Expression of TLRs in/on leukocytes in SRMA
(percentage of positive cells, median and 25%
to 75% range) (Continued)
Mix#
Healthy#
TLR5 95.3 (92.3 to 97.4) Healthy# Mix#
PB lymphocytes
TLR3 4.0 (3.1 to 5.8) none
TLR9 85.2 (71.2 to 92.8) none Pyo#
Healthy#
TLR2 6.4 (4.5 to 13.6) BM# MUE"
Healthy" Neopl"
TLR4 8.2 (3.8 to 13.5) BM# Pyo"
Healthy"
TLR5 6.125 (4.4 to 18.7) none BM#
Healthy"
BM, bacterial meningitis; Healthy, healthy dogs; Mix, miscellaneous diseases of
the nervous system; MUE, meningoencephalitis of unknown etiology; PMNs,
polymorphonuclear cells; Pyo, pyogenic infection; SRMA, steroid-responsive
meningitis-arteritis; SRMA A, SRMA acute; SRMA Th, SRMA under therapy; TLR,
Toll-like receptor.
(#) lower or (") higher values in comparison to SRMA A.
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to 94.9%; P<0.01) (see Figure 3C). The expression of
TLR2 positive monocytes in CSF did not statistically differ
among the groups; however, a tendency in SRMA A to
have a higher percentage of TLR2 positive monocytes
(median 87%; range 78.9 to 94.3%) in comparison with
MUE (median 26.2%; range 15.7 to 62.4%) was observed.
Higher percentages of TLR4 positive PB monocytes
were found in untreated SRMA dogs (SRMA A, median
95.6%; range 93.3 to 96.9%; P= 0.0032) and in dogs with
pyogenic infections (Pyo, median 97.2%; range 94.8 to
97.9%; P= 0.0015) in comparison to control group
(Healthy, median 84.8%; range 77.3 to 88.0%). SRMA
dogs under therapy showed a decrease in TLR4 positive
PB monocytes (SRMA Th, median 91.2%; range 86.6 to
95.5%; P= 0.019) in comparison to the untreated dogs
(see Figure 3D). The expression of TLR4 positive mono-
cytes in CSF did not statistically differ among the groups.
Similar to SRMA Th, MUE and Pyo, untreated SRMA
dogs showed higher percentage of TLR5 positive PB
monocytes (SRMA A, median 95.3%; range 92.3 to
97.4%; P= 0.0233) in comparison to healthy dogs
(Healthy, median 77.6%; range 27.4 to 91.6%). The
expression of TLR5 positive monocytes in CSF did not
statistically differ among the groups.
Dogs affected with SRMA showed higher percentages
of TLR3 positive PB monocytes (SRMA A, median 8.6%,
(See figure on previous page.)
Figure 2 Percentage of TLR positive PMNs in different disease categories. Boxes contain values from the 1st to the 3rd quartile, lines inside
boxes indicate median values, endpoints of vertical lines display the 5th to 95th percentile and • represent the outliers. Asterisks indicate
statistically significant differences (* P<0.05; ** P<0.01; *** P<0.005). BM, bacterial meningitis; CSF, cerebrospinal fluid; Healthy, healthy dogs; Mix,
miscellaneous diseases of the nervous system; MUE, meningoencephalitis of unknown etiology; PB, peripheral blood; PMNs, polymorphonuclear
cells; Pyo, pyogenic infection; SRMA, steroid-responsive meningitis-arteritis; SRMA A, SRMA Acute; SRMA Th, SRMA under therapy; TLR, Toll-like
receptor.
Figure 3 Precentage of TLR positive monocytes in different disease categories. Boxes contain values from the 1st to the 3rd quartile, lines
inside boxes indicate median values, endpoints of vertical lines display the 5th to 95th percentile and • represents the outliers. Asterisks indicate
statistically significant differences (* P<0.05; ** P<0.01; *** P<0.005). BM, bacterial meningitis; CSF, cerebrospinal fluid; Healthy, healthy dogs; Mix,
miscellaneous diseases of the nervous system; MUE, meningoencephalitis of unknown etiology; PB, peripheral blood; PMNs, polymorphonuclear
cells; Pyo, pyogenic infection; SRMA, steroid-responsive meningitis-arteritis; SRMA A, SRMA Acute; SRMA Th, SRMA under therapy; TLR, Toll-like
receptor.
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range 4.5 to 15.21%; P= 0.0073) in comparison to dogs
affected with pyogenic infections (Pyo, median 2.1%;
range 1.4 to 4%). Similar percentages have been found in
the remaining groups, with the exception of the healthy
controls (see Figure 3A). The expression of TLR3 posi-
tive monocytes in CSF did not statistically differ among
the groups.
Untreated dogs with SRMA showed higher (P= 0.003)
percentage of TLR9 positive PB monocytes (SRMA A,
median 92.13%; range 67.2 to 96.9%) in comparison to
healthy dogs (Healthy, median 38.8%; range 18.7 to
54%). Similar values were found also in the remaining
groups. In dogs with SRMA the expression of TLR9
positive PB monocytes statistically decreased (P= 0.0499)
Figure 4 Percentage of TLR positive lymphocytes in different disease categories. Boxes contain values from the 1st to the 3rd quartile, lines
inside boxes indicate median values, endpoints of vertical lines display the 5th to 95th percentile and • represents the outliers. Asterisks indicate
statistically significant differences (* P<0.05; ** P<0.01; *** P<0.005) BM, bacterial meningitis; CSF, cerebrospinal fluid; Healthy, healthy dogs; Mix,
miscellaneous diseases of the nervous system; MUE, meningoencephalitis of unknown etiology; PB, peripheral blood; PMNs, polymorphonuclear cells;
Pyo, pyogenic infection; SRMA, steroid-responsive meningitis-arteritis; SRMA A, SRMA Acute; SRMA Th, SRMA under therapy; TLR, Toll-like receptor.
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under therapy (SRMA Th median 77.1%; range 47.1 to
88.4%) (see Figure 3B). The expression of TLR9 positive
monocytes in CSF did not statistically differ among the
groups.
The fluorescence expression intensity did not differ
significantly among the examined groups; however, a
tendency of SRMA A in expressing higher TLR9 MFI in
PB PMNs in comparison to Pyo and Healthy was
observed.
Expression of TLRs on lymphocytes
Generally, lymphocytes of SRMA dogs were character-
ized by a decreased percentage of TLR2 and TLR4 posi-
tive cells in PB and decreased TLR4 expression in CSF
in comparison to other diseases, whereas TLR9 was
highly expressed in PB.
Dogs affected with SRMA showed lower percentages
(P= 0.0094) of TLR2 positive PB lymphocytes (SRMA A,
median 6.2%; range 1.5 to 13.6%) in comparison to
healthy dogs (Healthy, median 26.8%; range 18.1 to
38.9%). Similar findings were seen in the other groups,
with the exception of MUE and Neopl. The lowest
values were found in dogs with bacterial meningo-
encephalitis (BM, median 0.2%; range 1.8 to 0.1%), being
statistically lower than those found in SRMA A
(P= 0.0197) (see Figure 4C). SRMA A and SRMA Th
dogs also showed lower fluorescence intensity values
than Pyo and Healthy, being statistically relevant only
for SRMA Th (P <0.01). SRMA A had a higher percent-
age of TLR2 positive lymphocytes in CSF (median 13%;
range 8.1 to 18%) than BM (median 0.2%; range 0.1 to
0.7%) (see Figure 4D). Similar differences were observed
between these two groups in MFI values.
SRMA A (P= 0.0076) and the remaining groups (ex-
cept MUE and Pyo) had a lower percentage of TLR4
positive PB lymphocytes than Healthy (median 30.6%;
range 21.1 to 31.9%) (see Figure 4E). SRMA Th had
lower MFI values than Pyo (P= 0.0002) and Healthy
(P= 0.004). Dogs with untreated SRMA displayed statis-
tically lower (P <0.01) percentage of TLR4 positive lym-
phocytes in CSF (SRMA A, median 13%; range 3 to
23.9%) compared to SRMA dogs under therapy (SRMA
Th, median 43.8%; range 19.2 to 70.7%;) and dogs with
miscellaneous diseases of the nervous system (Mix, me-
dian 45.3%; range 33.4 to 56.2%) (see Figure 4F). In
SRMA A also the MFI values were statistically lower
(P= 0.0004) in comparison to SRMA Th.
The percentage of TLR5 positive lymphocytes in PB
and CSF did not differ among the groups. However, sig-
nificant differences among the groups were found in the
fluorescence expression intensity of TLR5 in PB lympho-
cytes. Dogs from both the SRMA A and SRMA Th
groups showed lower MFI values in comparison to dogs
affected with pyogenic diseases (P= 0.02 and P= 0.003,
respectively). Additionally, there was a tendency for
SRMA A towards lower MFI values in comparison to
healthy dogs, but this difference was statistically relevant
only for SRMA Th (P= 0.0056).
The percentage of TLR3 positive lymphocytes in PB in
dogs affected with SRMA did not differ from the other
groups (see Figure 4A). Also statistically relevant differ-
ences in TLR3 expression on CSF lymphocytes were not
found. Nevertheless, a tendency of a lower percentage of
TLR3 positive CSF lymphocytes in SRMA A (median
2.9%; range 1 to 11.6%) comparing to SRMA Th (median
19.35%; range 4.4 to 38.4%) was detected.
A higher percentage (P <0.05) of TLR9 positive PB
lymphocytes in untreated SRMA dogs (SRMA A, me-
dian 85.24%; range 71.2 to 92.8%) and under treatment
(SRMA Th, median 81.9%, range 33 to 89%) were found
in comparison to dogs with pyogenic diseases (Pyo, me-
dian 31.63%; range 6.6 to 51.4%) and healthy dogs
(Healthy, median 35.8%; range 24.2 to 49.6%) (see
Figure 4B). The percentage of TLR9 positive lympho-
cytes in CSF did not statistically differ among the inves-
tigated groups.
Discussion
In recent decades, studies on the etiopathogenesis of
SRMA mostly focused on the role of lymphocytes
[3,21,28,29]. Indeed, for many years the adaptive im-
mune system has been believed to play the most import-
ant role in triggering an inappropriate immune response.
However, more recently, the innate immune system
aroused much interest for its ability to modify the adap-
tive immune response, particularly in autoimmunity and
immune-mediated diseases [30,31]. TLRs are important
components of the innate immune system: their ability
to initiate and propagate inflammation protects the or-
ganism from infectious diseases [32]. On the other hand,
an excessive activation of these receptors may lead to
immune disorders [10,30,33,34]. The ambivalent role of
these receptors makes them interesting candidates for
immune pathological studies in SRMA patients, espe-
cially because CSF cells can be studied by systematic
flow cytometric studies in this large animal model. The
activation profile of TLRs in SRMA was tested to support
the hypothesis that these receptors are stimulated by in-
fectious antigens or endogenous proteins (self-antigens).
It was hypothesized that they are key factors for the initi-
ation of the inflammatory process and provide an indir-
ect hint of the etiology of the disease. Therefore, the
expression of TLRs in dogs affected with SRMA was
measured and compared to infectious diseases or other
neurological conditions.
The hypothesis that SRMA is maintained by a con-
tinuous bacterial infection had to be rejected by the
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current study. The comparison of TLRs expression pro-
files of SRMA dogs with dogs affected with bacterial/
pyogenic infection failed to show clear similarities be-
tween the two groups. In addition, the clear response to
long-term treatment with glucocorticosteroids does not
support a suspected classical bacterial infection [35-37].
However, triggering of an autoimmune reaction by bac-
teria cannot be ruled out completely in SRMA.
Indeed, TLR4 was statistically more frequently expressed
on monocytes of dogs with untreated SRMA and dogs
with pyogenic infections. TLR4 recognizes not only lipo-
polysaccharides, but also some endogenous ligands, such
as heat shock proteins (HSP60, HSP70), fibronectin, hya-
luronic acid, fibrinogen and heparan sulfate [32]. In the
current study, the triggering factor for increased TLR4
expression, a self or non-self antigen, was not examined.
A recent study showed that HSP 70 is elevated in SRMA
[38]. Therefore, it seems to be very likely that the trigger-
ing protein in SRMA might derive from a self-antigen
such as the HSP 70.
The role of TLR4 in human patients with sepsis, but
also in non-infectious diseases, such as inflammatory
bowel disease and rheumatoid arthritis, were studied
[39]. In the canine patient the role of TLR4 during sepsis
and the related systemic inflammatory response syn-
drome has still not been investigated. However, a poten-
tial role of TLR4 in dogs with osteoarthritis [40] and
chronic enteropathies [20] was proven.
The role of TLR4 for neutrophil recruitment into the
CNS was demonstrated in a murine model of systemic
inflammation [41]. Similar mechanisms might lead to
the invasion of neutrophils into the subarachnoidal
space in SRMA and explain the exorbitant neutrophilic
pleocytosis in acute cases. A recent study on human
large vessel vasculitides suggested that TLR4 is causing
transmural panarteritis [16]. Clinical and histopatho-
logical findings in dogs affected with SRMA include
neutrophilic leukocytosis, neutrophilic pleocytosis and
systemic vasculitis. Treatment with glucocorticosteroids
reduces these pathological processes and the expression
of TLR4 on monocytes declines significantly contempor-
arily (P= 0.019). These findings strongly suggest that
TLR4 plays an important role in triggering the described
pathological findings in SRMA. Additionally, it opens
the discussion for new treatment modalities, such as
anti-TLR4 antibodies and TLR4 antagonist; some com-
pounds from the latter class are already under clinical
trials for treatment of sepsis in human patients [39,42].
TLR9 seems to be constantly increased on PB leuko-
cytes in almost every disease examined in the current
study. However, patients with SRMA and dogs affected
with meningoencephalitides of unknown etiology
showed the highest expression of TLR9, suggesting a po-
tential role of this TLR in inflammatory CNS diseases
with a possible autoimmune component. TLR9 is pri-
marily involved in the recognition of bacterial DNA
[32]. In human medicine, TLR9 also seems to play an
important role in class-switching to pathogenic autoanti-
body production in systemic autoimmunity [11], sug-
gesting the possibility that an autoimmune reaction can
maintain the inflammatory process in SRMA. However,
the role of TLR9 inducing autoimmunity is controver-
sially discussed. TLR9 can have a more regulatory func-
tion [43] or enhance pathologic processes [19] in the
same animal model of multiple sclerosis. Further studies
are needed to elucidate the role of TLR9 in SRMA.
Dendritic cells, once activated by TLR4 and TLR9, pro-
duce interleukin-23 (IL-23), which subsequently activate
CD4+ T cells. The last are known to shift towards Th17-
differentiation under the effect of IL-6 and transforming
growth factor beta 1 (TGFβ1) [30,44]. This relatively new
class of T helper cells is believed to be involved in trig-
gering aberrant immune responses and recruiting neu-
trophils [45,46]. A recent study of our research group
showed the concomitant increased intrathecal produc-
tion of IL-6 and TGF beta-1 in dogs affected with SRMA
[47], suggesting a new hypothesis: that the aberrant im-
mune response in SRMA might be associated with Th17
cells maintaining the autoimmune reaction.
Although most TLR responses lead to inflammation,
there are studies suggesting an important role of TLRs
in homeostasis [43,48]. The role of certain TLRs has
been validated in different human diseases resulting in a
wide research area focusing on possible new treatment
strategies [42]. In case of such multivalent receptors, the
great challenge is to reduce the unnecessary inflamma-
tion without affecting regulatory functions of TLRs. For
example, many efforts attempt to find partial TLR4 ago-
nists, rather than antagonists, and some compounds are
already currently available for human use [39,42]. So far
in companion animals, the interest has been limited to
TLR ligands for developing new vaccines [49], but con-
sidering the rapid progress in human medicine, a similar
breakthrough is expected soon in veterinary medicine.
SRMA would be an ideal model to study such treatment
strategies.
Limitations of this study include the absence of true
controls, the number of patients in some groups and the
variation of the time of sampling in the course of the
disease. We tried to overcome the limitations comparing
a broad spectrum of different neurological diseases. In-
cluding only a few cases of a relatively uncommon dis-
ease in dogs, bacterial meningoencephalitis, might be
the reason TLRs in CSF samples were not statistically
comparable. We tried to overcome this limitation by in-
cluding dogs with pyogenic infections not affecting the
nervous system, since SRMA is considered to be a sys-
temic inflammatory disorder [23].
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Conclusion
We suggest that TLRs are involved in different aspects
of the pathogenesis of SRMA. This study supports the
hypothesis that an infectious agent can only trigger the
disease. SRMA itself seems to be maintained by multiple
alterations of the immune system resulting in an auto-
immune disease, TLRs, such as TLR4 and TLR9, might
act as receptors maintaining the inflammation.
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